Disclosures for "Long-term Efficacy and Safety of Risdiplam in Adults With 5q Spinal Muscular Atrophy (SMA): A Large Prospective Multi-centre Observational Study"
-
Dr. Hewamadduma has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Hewamadduma has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ARENX. Dr. Hewamadduma has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BIOGEN. Dr. Hewamadduma has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ROCHE. The institution of Dr. Hewamadduma has received research support from Neurocare . The institution of Dr. Hewamadduma has received research support from Sheffield Charitable Trust. Dr. Hewamadduma has received personal compensation in the range of $5,000-$9,999 for serving as a Adult Expert with National Health Service England (NHSE).
-
Dr. Yeo has nothing to disclose.
-
The institution of Jon Street has received research support from Sheffield Hospitals Charity.
-
Katie Nevin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche . Katie Nevin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.
-
Miss Accad has nothing to disclose.
-
Dr. Russell has nothing to disclose.